News Story: Full Text
Sponsored By
Cedars-Siani Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website

 

Exclusive: Interview With DelMar Pharmaceutical CEO Jeffrey Bacha

Al's Comment:

This drug, Val-083, might just be the next big step forward.  Late stage trials are about to start. It already had been approved in China for other diseases, and over 1,000 patients took it and have shown that toxicity is not a problem. It might especially be useful for gbm patients who have unmethylated MGMT.  

The article may have missed a little on the statistics. I doubt if 200,000 GBMs are diagnosed a year. They say "less than 200,000" but it is more like 20,000.

 


Posted on: 10/09/2016

Exclusive: Interview With DelMar Pharmaceutical CEO Jeffrey Bacha

 
Exclusive: Interview With DelMar Pharmaceutical CEO Jeffrey Bacha
Related
Events for the Week of Sept. 8-12
Related MRK
vTv Therapeutics Shares Initiated With Buy Rating, $13 Target
The Market In 5 Minutes: We're Waiting For You, Mrs. Yellen
October 2016's 'Worst' Very-Large-Cap CCC Stocks(Seeking Alpha)

Glioblastoma is a rare form of brain cancer that sees less than 200,000 new cases in the United States annually. Vancouver-based Biotech company DelMar Pharmaceuticals Inc DMPI 1.77% is making significant strides in fighting this rare disease.

With maximum treatment, glioblastoma remains a devastating disease, with the most common length of survival following diagnosis being 12–15 months, with less than 3–5 percent of people surviving longer than five years.

DelMar Pharmaceuticals is taking aggressive steps to combat this disease and create a more favorable outcome with those burdened with a glioblastoma diagnosis.

Its product, VAL-083, is under clinical trials and isn't just some moonshot therapy. It possesses a unique anti-cancer mechanism to overcome chemotherapy resistance, a major reason why most glioblastoma patients don't make it. The company will transition to a late state clinical development this year.

Related Link: Here's Why Seattle Genetics' Adcetris Is A $2 Billion Product

 

Essentially, VAL-083 attacks the tumor's DNA at a different point compared to current therapy. Another key differentiator with VAL-083 is that it crosses the blood brain barrier, something that most chemotherapies are currently incapable of. This further strengthens its ability to treat brain tumors, which has been the company's primary area of clinical focus to date.

"Median survival in the past had been 8 months for glioblastoma, just by adding our drug in addition to radiotherapy, lived 17 months, changing the game. There is clear evidence that we are going to do something in this population," said DelMar Pharmaceutical CEO Jeffrey Bacha in an exclusive Benzinga interview.

"We really believe this drug can have an impact for patients in some very important and very large big cancer, while that is exciting from an investor point of view, but also from a patient point of view where patients have very little options, it is life changing," added Bacha.

The market potential could be quite large. For example, Merck & Co., Inc. MRK 0.18%'s brain cancer drug Temodar generated $989 million in revenue in 2013 before it came off patent. Glioblastoma is a billion-dollar market.

"Even though we are starting out in a focused niche, it really does have true blockbuster potential," Bacha said.

DelMar Pharmaceutical's new clinical studies are making headway for some patients and families desperate to find a cure for this devastating disease.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please emailfeedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

 

Posted-In: cancer glioblastoma Jeffrey BachaBiotech Health Care Exclusives Interview General Best of Benzinga

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740